Amgen's earnings call highlights continued strong performance driven by volume growth across key products like Repatha, Prolia, and EVENITY.  Management's optimistic outlook for 2023, despite some price erosion, and the anticipated launch of AMGEVITA, suggests positive short-term momentum.  The potential impact of the Horizon acquisition and ongoing pipeline advancement further reinforces the positive outlook.
[1]
